Search Results for "moderate concentrate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for moderate concentrate. Results 101 to 110 of 149 total matches.
Comparison Table: Some Oral Antiseizure Medications (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
concentrations fall
after the first few weeks of
treatment
Risk of developmental
toxicity unclear; studies ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40 doi:10.58347/tml.2024.1708b | Show Introduction Hide Introduction
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
Nonopioid drugs for pain
were reviewed in a previous issue.2
ACUTE PAIN — For many types of moderate ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
, insomnia, confusion,
trouble concentrating, nausea, and vomiting can occur
when SSRIs are stopped ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
Celecoxib is a
moderate CYP2D6 inhibitor; it can increase serum
concentrations of CYP2D6 substrates.3 ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
Talazoparib (Talzenna) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
should be avoided. BCRP inhibitors can increase
talazoparib serum concentrations and the risk ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor talazoparib (Talzenna – Pfizer) has been
approved by the FDA for use in combination with the
androgen receptor blocker enzalutamide (Xtandi) for
treatment of adults with homologous recombination
repair (HRR) gene-mutated metastatic castration-resistant
prostate cancer (mCRPC). The drug has
been available since 2018 for treatment of deleterious
or suspected deleterious germline BRCA-mutated
(gBRCAm), HER2-negative locally advanced or
metastatic breast cancer.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e134-5 doi:10.58347/tml.2023.1682e | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for Abdominal Pain in Irritable Bowel Syndrome (IBS) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
and slowing of GI transit time ▪ Can reduce abdominal pain in patients with moderate to severe symptoms ...
View the Comparison Chart: Some Drugs for Abdominal Pain in Irritable Bowel Syndrome (IBS)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2 doi:10.58347/tml.2025.1721d | Show Introduction Hide Introduction
Vonoprazan (Voquezna) for Erosive Esophagitis
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
, may decrease serum concentrations of drugs
that require gastric acidity for absorption, such as
itraconazole ...
The FDA has approved vonoprazan (Voquezna –
Phathom), a potassium-competitive acid blocker, for
healing and maintenance of healing of all grades of
erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged
with amoxicillin (Voquezna Dual Pak) and with
amoxicillin and clarithromycin (Voquezna Triple Pak)
for treatment of Helicobacter pylori infection in adults.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):203-5 doi:10.58347/tml.2023.1692b | Show Introduction Hide Introduction
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025 (Issue 1734)
of
moderate to severe obstructive sleep apnea (OSA)
in adults with obesity.13 In two double-blind trials ...
Overweight is generally defined as a body mass
index (BMI) between 25 and 29.9 kg/m2 in adults. A
BMI ≥30 is considered obese (criteria differ slightly in
Asian patients). In patients with an elevated BMI, a
5-10% reduction in weight has been associated with
a reduction in the risk of developing type 2 diabetes,
hypertension, and dyslipidemia. Diet, exercise, and
behavior modification are the traditional methods
for losing weight, but they are often inadequate; the
American College of Cardiology no longer recommends
that all patients try lifestyle modification alone before
adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8 doi:10.58347/tml.2025.1734a | Show Introduction Hide Introduction
